{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:07:11Z","timestamp":1791648431049,"version":"4.3.4"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Observational comparative effectiveness studies can inform the positioning of biologic therapies for older patients with inflammatory bowel disease (IBD) who are underrepresented in clinical trials.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the effectiveness and safety of vedolizumab vs tumor necrosis factor (TNF) for older patients with IBD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This active comparator, new-user design, comparative effectiveness study was conducted between January 1, 2005, and December 31, 2018, among 754 older patients (aged \u226550 years) with IBD from the Danish National Patient Register. The mean follow-up after treatment initiation took place at 32 to 40 weeks. Statistical analysis was performed from February 1 to April 27, 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Treatment with vedolizumab or TNF antagonists.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary effectiveness outcome was treatment failure, defined as the composite risk of IBD-related hospitalization, IBD-related surgery, or a new corticosteroid prescription more than 6 weeks after initiation of treatment with biologic therapy. Secondary effectiveness outcomes were time to each individual component of the composite effectiveness outcome. The primary safety outcome was the risk of serious infections, defined as infections requiring hospitalization. A 1:1 propensity score\u2013matched analysis was conducted, accounting for patient-, disease-, and treatment-associated factors.<\/jats:p><\/jats:sec>Results<\/jats:title>The study compared 377 older patients with IBD with incident use of vedolizumab (202 women [53.6%]; mean [SD] age, 61.2 [8.3] years; 177 [46.9%] with Crohn disease) vs 377 patients with incident use of TNF antagonists (206 women [54.6%]; mean [SD] age, 61.3 [8.1] years; 182 [48.3%] with Crohn disease). Overall, vedolizumab was associated with an increased risk of treatment failure compared with TNF antagonists (1-year risk, 45.4% vs 34.7%; adjusted hazard ratio [HR], 1.31; 95% CI, 1.02-1.69), including higher risk of IBD-related hospitalization (1-year risk, 27.8% vs 16.3%; adjusted HR, 1.48; 95% CI, 1.03-2.15) and IBD-related major abdominal surgery (1-year risk, 21.3% vs 8.0%; adjusted HR, 2.39; 95% CI, 1.45-3.94). In subgroup analysis by IBD phenotype, among patients with Crohn disease, vedolizumab was associated with a 77% higher risk of treatment failure (adjusted HR, 1.77; 95% CI, 1.21-2.58), while no difference in risk of treatment failure was seen among patients with ulcerative colitis (adjusted HR, 1.04; 95% CI, 0.75-1.43; P<\/jats:italic>\u2009=\u2009.03 for interaction). There was no significant difference in the risk of serious infections, overall (1-year risk, 8.2% vs 8.7%; adjusted HR, 1.04; 95% CI, 0.58-1.85) and by IBD phenotype.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this comparative effectiveness study of older patients with IBD, vedolizumab was associated with a higher risk of treatment failure compared with TNF antagonists, particularly among patients with Crohn disease, without offering a significant safety advantage.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.34200","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:56:16Z","timestamp":1664553376000},"page":"e2234200","source":"Crossref","is-referenced-by-count":35,"title":["Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases"],"prefix":"10.1001","volume":"5","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla"},{"name":"Division of Biomedical Informatics, Department of Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aske T.","family":"Iversen","sequence":"additional","affiliation":[{"name":"Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine H.","family":"Allin","sequence":"additional","affiliation":[{"name":"Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark"},{"name":"Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Jess","sequence":"additional","affiliation":[{"name":"Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark"},{"name":"Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"issue":"5","key":"zoi220973r1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","article-title":"Past and future burden of inflammatory bowel diseases based on modeling of population-based data.","volume":"156","author":"Coward","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"zoi220973r2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.gastro.2022.03.016","article-title":"Disparities persist in inclusion of female, pregnant, lactating, and older individuals in inflammatory bowel disease clinical trials.","volume":"163","author":"Rabinowitz","year":"2022","journal-title":"Gastroenterology"},{"issue":"11","key":"zoi220973r3","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.cgh.2020.02.048","article-title":"Progression of elderly onset inflammatory bowel diseases: a systematic review and meta-analysis of population-based cohort studies.","volume":"18","author":"Rozich","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"zoi220973r4","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1097\/MIB.0000000000000817","article-title":"Age disparities in the use of steroid-sparing therapy for inflammatory bowel disease.","volume":"22","author":"Govani","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"14","key":"zoi220973r5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease.","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi220973r6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","article-title":"Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report: part I.","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"issue":"2","key":"zoi220973r7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/00365529609031980","article-title":"Assessment of the diagnoses of Crohn\u2019s disease and ulcerative colitis in a Danish hospital information system.","volume":"31","author":"Fonager","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"zoi220973r8","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/gutjnl-2013-305607","article-title":"Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011.","volume":"63","author":"Rungoe","year":"2014","journal-title":"Gut"},{"key":"zoi220973r9","doi-asserted-by":"publisher","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-a inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ"},{"issue":"23","key":"zoi220973r10","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-a antagonists and risk of cancer in patients with inflammatory bowel disease.","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"zoi220973r11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study.","volume":"69","author":"Kirchgesner","year":"2020","journal-title":"Gut"},{"issue":"7","key":"zoi220973r12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/gut.2010.228585","article-title":"Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study.","volume":"60","author":"Kappelman","year":"2011","journal-title":"Gut"},{"issue":"5","key":"zoi220973r13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"10132","key":"zoi220973r14","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study.","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"zoi220973r15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2202\/1557-4679.1198","article-title":"Comparing approaches to causal inference for longitudinal data: inverse probability weighting versus propensity scores.","volume":"6","author":"Ertefaie","year":"2010","journal-title":"Int J Biostat"},{"issue":"7","key":"zoi220973r16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.v33.7","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"3","key":"zoi220973r17","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.2307\/2533867","article-title":"A simple test for independent censoring under the proportional hazards model.","volume":"54","author":"Lee","year":"1998","journal-title":"Biometrics"},{"issue":"10","key":"zoi220973r18","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis.","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"zoi220973r19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis.","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"zoi220973r20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cgh.2021.08.047","article-title":"Vedolizumab Is associated with a lower risk of serious infections than anti-tumor necrosis factor agents in older adults.","volume":"20","author":"Kochar","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"zoi220973r21","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s10620-021-07200-1","article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn\u2019s disease in population-based cohort studies.","volume":"67","author":"Tsai","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"10","key":"zoi220973r22","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn\u2019s Disease: A Meta-Analysis of Population-Based Cohorts.","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"zoi220973r23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/ibd\/izab163","article-title":"Efficacy of vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients.","volume":"28","author":"Khan","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"zoi220973r24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"issue":"2","key":"zoi220973r25","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.cgh.2021.02.032","article-title":"Comparative risk of serious infections with tumor necrosis factor a antagonists vs vedolizumab in patients with inflammatory bowel diseases.","volume":"20","author":"Singh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"zoi220973r26","doi-asserted-by":"publisher","journal-title":"Am J Gastroenterol","DOI":"10.1038\/ajg.2012.218"},{"key":"zoi220973r27","doi-asserted-by":"publisher","journal-title":"Am J Gastroenterol","DOI":"10.1038\/s41395-018-0098-4"},{"issue":"8","key":"zoi220973r28","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/apt.16073","article-title":"Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease\u2014a prospective multicentre cohort study.","volume":"52","author":"Asscher","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"zoi220973r29","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1053\/j.gastro.2020.02.032","article-title":"Pretreatment frailty is independently associated with increased risk of infections after immunosuppression in patients with inflammatory bowel diseases.","volume":"158","author":"Kochar","year":"2020","journal-title":"Gastroenterology"},{"issue":"10","key":"zoi220973r30","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/ibd\/izaa327","article-title":"Frailty and risk of serious infections in biologic-treated patients with inflammatory bowel diseases.","volume":"27","author":"Singh","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"zoi220973r31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/pds.v17:9","article-title":"Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis.","volume":"17","author":"Grijalva","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2796853\/singh_2022_oi_220973_1663946869.79269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:56:20Z","timestamp":1664553380000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2796853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.34200","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}